Background {#Sec1}
==========

Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, arising from the Interstitial Cells of Cajal. The most common location is the stomach (60%), followed by the jejunum and ileum (30%), duodenum (5%), and colorectum (\< 5%), with rare reported cases arising in the esophagus, appendix, and gallbladder. Initially thought to be tumors of smooth muscle, advances in immunohistochemistry and molecular genetics have found that this is not the case. Specifically, most GISTs express KIT (CD 117, c-KIT), a highly sensitive and specific marker for GIST, while leiomyomas and leiomyosarcomas do not \[[@CR1]\]. Anoctamin 1 (ANO1, DOG1), is another tissue marker that can be useful in the diagnosis of GIST \[[@CR2]\]. GISTs are largely benign, but up to 30% may have malignant behaviors determined by the mitotic rate, primary site, size, and metastasis, most commonly to the liver, lung, and bone \[[@CR1], [@CR2]\]. Intracranial metastasis is rare and presents unique treatment challenges.

Imatinib, the mainstay medical treatment for GIST, does not cross the blood-brain barrier, and as such may offer limited clinical benefit to patients with intracranial metastasis \[[@CR3]\]. Nevertheless, some authors have reported success in the treatment of intracranial GIST metastasis with imatinib \[[@CR4]\]. Sunitinib, another tyrosine kinase receptor antagonist, is sometimes used as a second-line therapy in patients with metastatic GIST \[[@CR5]\]; however, its role in the management of intracranial metastasis remains undetermined. Radiotherapy for metastatic GIST has not been definitively shown to be effective \[[@CR1]\], as they are generally considered radioresistant, but little data exists regarding the treatment of intracranial GIST metastases with radiation. Despite this, some series have proposed a role for radiation therapy, especially for tumors that are surgically unfavorable \[[@CR3]\].

Here, we present a case of intracranial metastasis of GIST with a discussion of relevant literature regarding this rare clinical scenario. We aim to study our current case with respect to historical studies to better investigate the best course of treatment for patients with this rare manifestation of GIST.

Methods {#Sec2}
=======

A thorough systematic review of the literature was performed through the databases Embase and Pubmed from dates of inception to May 2019 to identify cases of GIST metastatic to the brain. The string "'gastrointestinal stromal tumor' AND brain AND metastasis"" was used as either keywords or Medical Subject Headings terms to identify all eligible studies. Inclusion and exclusion criteria from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to vet the retrieved articles \[[@CR6]\]. For the purposes of this review, cases were included only if they described intradural metastases rather than calvarial or intraorbital metastases. Abstracts, conference presentations, and editorials were excluded. As there is a paucity of cases in the literature, cases were included regardless of date of publication, source of publication, or inclusion in previous literature reviews. Studies were reviewed by a single reviewer (M.P.), and the senior investigator (A.P.) reviewed the final results. Data regarding demographics, modality of treatment, and treatment response were recorded for each case where available.

Case presentation {#Sec3}
=================

A 57-year-old woman with known history of biopsy-proven GIST metastatic to the liver presented with a six-week history of left facial weakness, difficulty closing her left eye (House-Brackmann 4), complete left hearing loss, and left facial numbness. She had been previously diagnosed at an outside institution and initiated on imatinib (400 mg daily) 3 months prior to presentation, In the week prior to presentation, she had developed headaches, gait disturbance, and dizziness. MRI revealed a contrast-enhancing dural-based left middle cranial fossa mass measuring 2.9 cm × 3.1 cm × 3.4 cm with extension into the internal auditory canal and associated cerebral edema (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Representative T1-weighted post-contrast images preoperatively (**a**) and postoperatively (**b**). Pre-operative (**a**) and post-operative (**b**) coronal MRI, T1-weighted-post contrast. A lobulated, homogenously enhancing lesion is seen to be arising from the dura of the middle fossa and tentorium and compressing the temporal lobe. Gross total resection is noted in the post-operative image

The patient underwent left temporal craniotomy to excise the lesion without complication. Intraoperative pathology revealed a spindle cell neoplasm. Her post-operative course was uncomplicated; after an overnight stay in the ICU, the patient was transferred to the floor and discharged to a rehabilitation facility at her preoperative baseline. Postoperative MRI demonstrated gross total resection of the lesion. Microscopically, the tumor demonstrated sheets of spindled tumor cells with short ovoid, irregular, hyperchromatic nuclei and scattered large atypical nuclei without extensive necrosis (Fig. [2](#Fig2){ref-type="fig"}a-d). Immunohistochemical staining with appropriate controls was positive for KIT (Fig. [2](#Fig2){ref-type="fig"}e) and ANO1 (DOG1) (Fig. [2](#Fig2){ref-type="fig"}f), confirming diagnosis of metastatic GIST from the initial gastric tumor (Fig. [2](#Fig2){ref-type="fig"}g-h). She was subsequently re-initiated on imatinib (400 mg daily) as an outpatient following craniotomy.

Results {#Sec4}
=======

The initial database query yielded 192 publications after duplicates were removed. Screening of these publications based on abstracts yielded 24 publications, which was then further refined to 18 after the exclusion of 6 articles discussing GIST and metastases not to the brain (Fig. [3](#Fig3){ref-type="fig"}). These 18 articles were then included for review. Fig. 2Pathology Slides. **a** Metastatic Intradural Tumor: The tumor is very cellular consisting of sheets of tumor cells (hematoxylin-eosin, original magnification X20). **b** Metastatic Intradural Tumor: The cells are haphazardly arranged and spindled with short, ovoid, irregular, hyperchromatic nuclei with scattered large atypical nuclei (hematoxylin-eosin, original magnification X200). **c**, **d** Metastatic Intradural Tumor: The cytoplasm is eosinophilic and moderate in amount with variable vacuolization. Occasional nuclear inclusions are seen. (hematoxylin-eosin, original magnification X400). **e**, **f** Metastatic Intradural Tumor: The tumor cells are diffusely positive for KIT (CD117) (**e**) and ANO-1 (DOG**-**1) (**f**) immunohistochemical stains (original magnification X400). **g**, **h** The original gastric biopsy shows a subepithelial tumor consisting of predominantly bland small epithelioid spindled cells with vacuolated cytoplasm and smudged chromatin. Rare large cells are noted, but not to the extent seen in the metastatic tumor (hematoxylin-eosin, original magnification X20 and X200, respectively) Fig. 3Systematic Review Flow Diagram

In our review of the literature, only 18 cases of GIST with intracranial metastases were identified, and these are summarized in Table [1](#Tab1){ref-type="table"}. With the inclusion of our present case, 15 of 19 patients were male, and mean age was 58 years old (range 15--80 years, standard deviation 17.4 years). The primary site of the GIST in these patients was variable throughout the GI tract with the most common involving the small intestine (9 out of 19 cases) and the stomach (5 out of 19 cases). Additionally, although it was not reported in every case, any sites of intraperitoneal metastasis were also quite variable within this series with the most common site being the liver. With regards to sites of brain metastasis, there was a large predilection for the cerebrum, with only one case of metastasis solely to infratentorial elements, namely the pontomedullary junction and the cerebellum \[[@CR7]\]. The tumors in seven of the cases, including the case reported here, either involved or originated from the dura \[[@CR4], [@CR8]--[@CR12]\]. There was one metastasis to the pituitary \[[@CR13]\]. Radiographically, the tumors reported tended to have appearances similar to other intracranial metastases, being relatively well-circumscribed and contrast-enhancing. Fourteen patients underwent chemotherapy (4 as stand-alone therapy, 10 in conjunction with other treatments), 13 patients had total resection (all in conjunction with other treatments), eight patients underwent radiation therapy (1 as stand-alone therapy, 7 in conjunction with other treatments), and four patients had stereotactic radiosurgery (all in conjunction with other treatments). Eight patients died following treatment of their intracranial disease. Of these, the average time to death was 9.6 months (range 3.5--35 months, standard deviation 10.6 months). These data are summarized in Table [1](#Tab1){ref-type="table"}. Table 1Summary of Studies Included in Systematic ReviewCaseAgeSexPrimaryCNS siteSize of CNS lesionOther MetsInterval between diagnosis and CNS metastasisTreatment of CNS tumorMutation StatusOutcome (from time of CNS diagnosis)1Akiyama 2004 \[[@CR8]\]60MSmall bowelLeft cavernous sinusNRL5-S1 vertebra7 yearsRadiation (54 Gy), not further describedNRDeath at 8 months2Badri 2018 \[[@CR15]\]66MSmall BowelRight cerebellar hemisphere4 cmNRCNS lesion found firstTotal resection of cerebellar tumor with adjuvant radiation and chemotherapy (no further details given)NRRemission at 12 months3Brooks 2002 \[[@CR4]\]75MMesenteryBoth hemispheres, (dural based)InfiltrativeLiver14 monthsImatinib 400 mg twice dailyNRRemission at 4 months4Drazin 2012 \[[@CR16]\]57MStomachLeft cerebellar, left frontal3 cm for cerebellar lesion, size of frontal lesion not providedNR13 monthsTotal resection for cerebellar lesions, SRS (18 Gy) to frontal lesionNRRemission at 15 months5Gerin 2007 \[[@CR7]\]45MSmall bowelPontomedullary junction, cerebellum, leptomeninges2 cm for primary lesion, others very smallNR5 yearsImatinib 800 mg dailyNRDeath at "a few weeks"6Hamada 2010 \[[@CR17]\]54FEsophagusLeft frontal lobe5 cmLiver6 yearsNeoadjuvant imatinib 400 mg daily, then total resection, SRS (dose not reported)KIT (exon 11)Remission at 6 months7Hughes 2004 \[[@CR9]\]47MJejunumLeft parasagittal (dural based)NRLiver25 MonthsTotal resection, Imatinib 800 mg dailyKIT (exon 9)Death at 35 months8Inage 2002 \[[@CR10]\]70MStomachLeft occipital, (dural based)5.5 cmLung10 yearsTotal resection and radiation, not further describedNRDeath at 8 months9Jagannathan 2012 \[[@CR11]\]15MStomachRight Frontoparietal, (dural based)4.2 cm × 3.3 cm × 3.1 cmLiver12 yearsMany TK inhibitors prior to discovery of CNS lesion, Total resectionNo mutation in KIT or PDGFR alphaRemission at 6 months10Janku 2011 \[[@CR18]\]56FStomachMany small lesionsNRLung, liver, pelvis3 weeksImatinib 400 mg daily, then 600 mg dailyNRNR11Kajikawa 2005 \[[@CR19]\]76MJejunum and DuodenumRight parietal, Right cerebellar hemisphere2 cmNR4 monthsImatinib 400 mg daily, radiation (WBRT 40 Gy)No mutation in KITDeath at 4 months12Kaku 2006 \[[@CR12]\]68FPerisacralRight parietal lobe, (dural based)3 cmNR2 yearsTotal resection, imatinib 800 mg dailyNRRemission13Naoe 2011 \[[@CR20]\]77MJejunumRight cerebral peduncle, left occipital lobe2.4 cm, 2.2 cmNRCNS lesion found firstTotal resection, WBRT (39 Gy), imatinib 400 mg dailyNo KIT mutation or PDGFR alphaDeath at 4 months14O'Halloran 2017 \[[@CR13]\]61MNRPituitary1.5 cm × 3.5 cm × 2 cmNRNRTotal resection, SRS and imatinib not further describedNRNR15Puri 2006 \[[@CR21]\]42MMesenteryRight Parietal lobe3.5 cmNRCNS lesion found firstTotal resection, WBRT (60 Gy), imatinib 600 mg daily, multiple cytotoxic chemotherapy regimensNRDeath at 10 months16Sato 2014 \[[@CR22]\]80MSmall bowelCerebellar vermis, Right frontal lobe4 cmCardiac apex, subclavian vesselsCNS lesion found firstTotal resection, radiotherapy (22 Gy) not further describedNRDeath at 4 months17Takeuchi 2014 \[[@CR5]\]74MJejunumRight prefrontal gyrus1.4 cm ×1.5 cmLiver6 yearsSunitinib 50 mg daily, SRS not further describedNRRemission at 9 months18Wong 2011 \[[@CR23]\]26MDuodenumLeft frontotemporal6.1 cm ×4.1 cmLiver6 yearsTotal resection, radiation not further describedNRRemission at 4 months19Present case57FEsophagus and stomachLeft temporal, (dural based)2.9 cm × 3.1 cm × 3.4 cm.Liver6 monthsTotal resection, imatinib 400 mg dailyNRFollow-up in progress*CNS*, Central Nervous System; *Mets*, Metastases; *M*, Male; *F*, Female; *NR*, Not Reported; *TK*, Tyrosine Kinase; *PDGFR*, Platelet-derived growth factor receptor; *SRS*, Stereotactic radiosurgery; *WBRT*, Whole Brain Radiation Therapy

Discussion and conclusion {#Sec5}
=========================

Metastatic GIST to the brain is a rare clinical entity requiring unique considerations for treatment. Interestingly, there was substantial variation in the treatment of these patients, reflecting the lack of evidence-based guidelines for treatment of intracranial GISTs. Nevertheless, treatment regimens in reviewed papers generally include combinations of surgery, radiotherapy, and systemic chemotherapy with tyrosine kinase inhibitors, similar in concept to treatment of other intracranial metastases. Thirteen of nineteen patients reported here underwent treatment with tyrosine kinase inhibitor therapy, while the other six patients received no specific chemotherapy. Traditionally, treatment of advanced or metastatic GIST has been challenging due to the tumor's resistance to cytotoxic chemotherapeutic agents \[[@CR11]\]. With the identification of the KIT gene, the development of targeted tyrosine kinase inhibitors has improved the response to medical treatment. Indeed, the presence of KIT gene is positively correlated with susceptibility to tyrosine kinase inhibitor therapy \[[@CR3]\]. One study noted an initial reduction in intracranial tumor burden with sunitinib treatment, but noted that several weeks after initiation of treatment, a new brain metastasis developed which was then successfully treated with radiation \[[@CR5]\]. The patient was started on imatinib, but after it proved ineffective, was switched to sunitinib. Although imatinib is known to have poorer CNS penetration, any clear advantage of sunitinib over imatinib in the treatment of GIST metastatic to the CNS is unlikely to be demonstrated with so few cases. Nevertheless, sunitinib and other tyrosine kinase inhibitors that have better CNS penetration remain interesting targets for future research.

GIST, similar to the histologically-similar soft tissue sarcomas, is generally considered to be radioresistant. As such, radiation has been considered to have a limited role in treatment. Nevertheless, some series have reported at least a good palliative effect of radiotherapy for GIST metastases that are refractory to therapy or not amenable to surgery \[[@CR14]\]. Eight patients in this series underwent radiation therapy of some kind. The use of conventional radiation versus radiosurgery was variable, as were the radiation doses when reported. Additionally, only one patient reported underwent radiation without additional therapy, in the case of a cavernous sinus metastasis.

Finally, surgery consisting of local control of intracranial disease with adjuvant therapy remains a useful treatment modality for metastatic GIST, especially with regards to intracranial metastases \[[@CR3], [@CR17], [@CR18]\]. Intracranial surgery is especially reasonable when metastasis is small, localized, and superficial (cortical/subcortical). Nevertheless, many case series and reports describe cases of metastatic GIST with good response to radiation or chemotherapy alone. Given these other reports of tumors responsive to chemotherapy and radiation, it seems more investigation is required to determine the best course of treatment for patients with this unusual sequela of GIST.
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